Open AccessPI‐02: FOLLOW‐UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
Author(s) -
M. VAN DIJK,
M. RAB,
B. VAN OIRSCHOT,
J. BOS,
C. DERICHS,
A. RIJNEVELD,
M. CNOSSEN,
E. NUR,
B. BIEMOND,
M. BARTELS,
J. JANS,
W. VAN SOLINGE,
R. SCHUTGENS,
R. VAN WIJK,
E. VAN BEERS
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000872868.40573.13
Subject(s) - pyruvate kinase , medicine , deoxygenation , adverse effect , hemolysis , hemoglobin , allosteric regulation , dosing , glycolysis , clinical endpoint , hypoxia (environmental) , pyruvate kinase deficiency , gastroenterology , pharmacology , oxygen , clinical trial , receptor , chemistry , biochemistry , metabolism , organic chemistry , catalysis